Braingaze
Braingaze is a pioneering startup in the mental health diagnostics and therapy sector that has created an ADHD-diagnosing video game. This technology leverages over 20 years of research experience into eye movement by neuroscientist Hans Super at the University of Barcelona.
Their solutions provide early detection, diagnosis and therapy of neuro-cognitive problems, specifically for people with Attention Deficit and Hyperactivity Disorder (ADHD) affecting 12 million people, and those with Alzheimer's Disease (AD), affecting 50 million people.
In March 2024, Braingaze secured a €1.5m investment, led by RYSE Asset Management. RYSE leveraged their operational experience and network relationships with healthcare systems, pharma and medical device companies by implementing a set of impact metrics that are particularly salient for Braingaze:
- Progressing health outcomes: leveraging years of clinical data the initial diagnostic tool and upcoming therapeutic tool reduce waiting times for diagnosis and improve outcomes for those diagnosed with ADHD.
- Patient experience: the video game improves the experience, particularly for children.
- Patient access: highly scalable solution that can be deployed in hard-to-reach areas globally. - Value chain: Braingaze is creating new classes of intervention that deliver impact.
Since closing their investment round, Braingaze have secured a contract with Tris Pharma in the US which has helped to extend the reach of their ADHD diagnostic solutions to patients in the US and Canada.
